MARKET

PDLI

PDLI

PDL BioPharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.595
+0.645
+21.86%
Closed 18:55 12/09 EST
OPEN
3.450
PREV CLOSE
2.950
HIGH
3.680
LOW
3.320
VOLUME
5.79M
TURNOVER
--
52 WEEK HIGH
3.890
52 WEEK LOW
2.060
MARKET CAP
410.49M
P/E (TTM)
-129.3165
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PDLI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PDLI News

  • Why Shares of PDL BioPharma Are Soaring Today
  • MotleyFool.com.16h ago
  • BLUE, PCG among premarket gainers
  • Seeking Alpha - Article.18h ago
  • PDL BioPharma Reviews Strategic Review, Will Halt Execution of its Growth Strategy and Focus on Returning Proceeds from Asset Sales to Shareholders, Announces $200M Buyback
  • Benzinga.20h ago
  • PDL BioPharma Announces Completion of Strategic Review Process
  • PR Newswire.20h ago

More

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Name
Price
%Change

About PDLI

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
More

Webull offers PDL BioPharma Inc (PDLI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.